NCT04051944View on ClinicalTrials.gov

A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 21, 2019

Primary Completion Date

November 10, 2021

Study Completion Date

November 10, 2021

Conditions

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Interventions

DRUG

Rozanolixizumab

Subjects will receive rozanolixizumab in a specified sequence during the treatment period.

Trial Locations (14)

27710

Cidp04 50080, Durham

28210

Cidp04 50117, Charlotte

30912

Cidp04 50075, Augusta

85251

Cidp04 50082, Scottsdale

Unknown

Cidp04 40169, Ghent

Cidp04 40002, Leuven

Cidp04 40120, Liège

Cidp04 40126, Copenhagen

Cidp04 40170, Strasbourg

Cidp04 40134, Essen

Cidp04 40140, Göttingen

Cidp04 40034, Amsterdam

Cidp04 40160, Barcelona

Cidp04 40167, Sheffield

All Listed Sponsors

lead

UCB Biopharma SRL

INDUSTRY

NCT04051944 - A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Biotech Hunter | Biotech Hunter